Novartis ESMO Event Presentation

Pluvicto halved the number of symptomatic skeletal events (SSE)1 and prolonged time without SSE vs. ARPI change 177 Lu-PSMA-617 (n = 234) Number of events, n (%) SSE Death 25 (10.7) 21 (9.0) ARPI change (n=234) 59 (25.2) 54 (23.1) 4 (1.7) Median time to SSE, months (95% CI) NE (NE, NE) 5 (2.1) NE (15.6, NE) HR (95% CI) 0.35 (0.22, 0.57) 1. SSE defined as the first new symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgical intervention, requirement for radiation therapy to relieve bone pain or death from any cause 18 NOVARTIS ESMO EVENT | OCTOBER 24, 2023 | INVESTOR PRESENTATION NOVARTIS | Reimagining Medicine

View entire presentation